The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Self-citation
Cited by
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
Beltran, H., Prandi, D., Mosquera, J. M., Benelli, M., Puca, L., Cyrta, J., Marotz, C., Giannopoulou, E., Chakravarthi, B. V. S. K., Varambally, S., et al. (2016) · Nature Medicine · doi:10.1038/nm.4045 · Cited by 1,685
Self-citationAggarwal, R., Huang, J., Alumkal, J. J., Zhang, L., Feng, F. Y., Thomas, G. V., Weinstein, A. S., Friedl, V., Zhang, C., Witte, O. N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6880 · Cited by 810
Self-citationProstate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
Schaeffer, E. M., Srinivas, S., Adra, N., An, Y., Barocas, D., Bitting, R., Bryce, A., Chapin, B., Cheng, H. H., D’Amico, A. V., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0050 · Cited by 596
Cellular plasticity and the neuroendocrine phenotype in prostate cancer
Davies, A. H., Beltran, H., & Zoubeidi, A. (2018) · Nature Reviews Urology · doi:10.1038/nrurol.2018.22 · Cited by 431
Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer
Paschalis, A., Sheehan, B., Riisnaes, R., Rodrigues, D. N., Gurel, B., Bertan, C., Ferreira, A., Lambros, M. B. K., Seed, G., Yuan, W., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.06.030 · Cited by 455
Aggressive Variants of Castration-Resistant Prostate Cancer
Beltran, H., Tomlins, S., Aparicio, A., Arora, V., Rickman, D., Ayala, G., Huang, J., True, L., Gleave, M. E., Soule, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3309 · Cited by 420
Self-citationCancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Parker, C., Gillessen, S., Heidenreich, A., & Horwich, A. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv222 · Cited by 415
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0
Fendler, W. P., Eiber, M., Beheshti, M., Bomanji, J., Calais, J., Ceci, F., Cho, S. Y., Fanti, S., Giesel, F. L., Goffin, K., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-06089-w · Cited by 410
Clinical features of neuroendocrine prostate cancer
Conteduca, V., Oromendia, C., Eng, K. W., Bareja, R., Sigouros, M., Molina, A., Faltas, B. M., Sboner, A., Mosquera, J. M., Elemento, O., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.08.011 · Cited by 356
Self-citationWang, H. T., Yao, Y. H., Li, B. G., Tang, Y., Chang, J. W., & Zhang, J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.3553 · Cited by 314
Sheikhbahaei, S., Afshar-Oromieh, A., Eiber, M., Solnes, L. B., Javadi, M. S., Ross, A. E., Pienta, K. J., Allaf, M. E., Haberkorn, U., Pomper, M. G., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3780-7 · Cited by 295
Beltran, H., Oromendia, C., Danila, D. C., Montgomery, B., Hoimes, C., Szmulewitz, R. Z., Vaishampayan, U., Armstrong, A. J., Stein, M., Pinski, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1912 · Cited by 290
Self-citationPD-L1 is highly expressed in Enzalutamide resistant prostate cancer
Bishop, J. L., Sio, A., Angeles, A., Roberts, M. E., Azad, A. A., Chi, K. N., & Zoubeidi, A. (2015) · Oncotarget · doi:10.18632/oncotarget.2703 · Cited by 279
The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer
Akamatsu, S., Wyatt, A. W., Lin, D., Lysakowski, S., Zhang, F., Kim, S., Tse, C., Wang, K., Mo, F., Haegert, A., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.012 · Cited by 279
Self-citationPI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance
Hsieh, A., & Edlind, M. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122876 · Cited by 276
A Convergence-Based Framework for Cancer Drug Resistance
Konieczkowski, D. J., Johannessen, C. M., & Garraway, L. A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.025 · Cited by 258
Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer
Wyatt, A. W., Mo, F., Wang, K., McConeghy, B., Brahmbhatt, S., Jong, L., Mitchell, D. M., Johnston, R. L., Haegert, A., Li, E., et al. (2014) · Genome Biology · doi:10.1186/s13059-014-0426-y · Cited by 82
Metadata
- Authors
- Beltran, H., Tagawa, S. T., Park, K., MacDonald, T., Milowsky, M. I., Mosquera, J. M., Rubin, M. A., & Nanus, D. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-12-20
- Volume
- 30
- Issue
- 36
- Pages
- e386-e389
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2149937232
- Cited by
- 229
- References
- 3
- FWCI
- 13.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.